Abstract:Objective: To detect the expression of miR-221/222 in serum and plasma cells in patients with monoclonal gammopathy of undetermined significance(MGUS) and multiple myeloma(MM), and to explore the possibility of miR-221/222 as biomarkers in the diagnosis and prognosis predicting of MGUS and MM. Methods: Bone marrow and serum samples from 14 patients with newly diagnosed MGUS, 81 patients with newly diagnosed or relapsed MM and 10 controls were collected from Sir Run Run Shaw Hospital of Zhejiang University and Tongde Hospital of Zhejiang Province during January 2013 and December 2015. The expressions of miR-221/222 in serum and in sorted CD138 positive plasma cells were detected by qRT-PCR, and the relative expression of miR-221/222 (Δct) was compared between the groups. Serum levels of miR-221 before and after treatment were compared in both remission group (n=22) and refractory group (n=13) in MM patients, and its correlation with serum level of β2-MG was assessed using Pearson's correlation analysis. Results: Serum levels of miR-221/222 in MGUS and MM groups were significantly higher than those in control group (all P<0.01), while miR-221/222 levels in plasma cells were significantly lower in MGUS and MM groups than those in the control group (P<0.05 or<0.01). No significant difference in miR-221/222 levels in serum and plasma cells was observed between MGUS group and MM group (all P>0.05). There was no correlation between miR-221/222 levels in serum and plasma cells (r=0.024 and -0.127, all P>0.05), but miR-221 levels were correlated with miR-222 levels in both serum and plasma cells (r=0.534 and 0.552, all P<0.01). Receiver operating characteristic (ROC) curves showed that the areas under the curve (AUCs) of serum miR-221/222, plasma cell miR-221/222 in diagnosis of MGUS/MM were 0.968, 0.976, 0.801 and 0.727, respectively. There was no significant difference in serum level of miR-221 among MM patients with different paraprotein isotypes (P>0.05), but serum level of miR-221 in patients with relapsed MM was higher than that in patients with newly diagnosed MM (P<0.01). Compared with the patients with MGUS or MM stageⅠ and Ⅱ, patients with MM stage Ⅲ were of higher serum levels of miR-221 (P<0.01). Serum level of miR-221 decreased after chemotherapy in the remission group (U=51.5, P<0.01), but such decrease was not observed in the refractory group (U=67.5, P>0.05). Serum level of β2-MG was positively correlated with serum level of miR-221 (r=0.524, P<0.01). Conclusion: miR-221/222 in serum and plasma cells may be biomarkers for early diagnosis of MGUS, and are helpful for diagnosis and efficacy evaluation of MM.

Application of Detection of IgH Gene Rearrangements in the Patients with Multiple Myeloma

The application of detection of rearrangement of IgH gene clonality in B cell lymphoma

[Detection of IgH Gene Rearrangement in B-cell Non-Hodgkin's Lymphoma and Application of Gel-Scan Method].

Significance of Clonal Gene Rearrangements of Immunoglobulin Heavy Chain and T-cell Receptor Γ in Acute Nonlymphoblastic Leukemia

The detection of gene rearrangements of non-Hodgkins lymphoma and its clinical significance

Analysis of Tumor Specific Immunoglobulin Gene Rearrangement in Peripheral Blood B-cells of Multiple Myeloma Patients by a PCR-SSCP Method.

Rapid Detection of Immunoglobulin Heavy Chain Gene Rearrangement by PCR and Melting Curve Analysis Using Combined FR2 and FR3 Primers

[Expression of Microrna-221/222 in Patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma].

Clinical Implications of C-Maf Expression in Plasma Cells from Patients with Multiple Myeloma

[Detection of the Cytogenetic Aberrations in Multiple Myeloma by Using Microrray Comparative Genomic Hybridization].

Identification of Immunoglobulin Gene Rearrangement Biomarkers in Multiple Myeloma through cfDNA-Based Liquid Biopsy Using tchDNA-Seq

[Detection of Molecular Cytogenetic Aberrations by Fluorescence in Situ Hybridization in Different Bone Marrow Samples of Multiple Myeloma].

Study of Immunoglobulin and T-cell Receptor Gene Rearrangements in Patients with Non-Hodgkin' S Lymphoma

The Detection of the Immunophenotyping of Plasma Cells in Patients with Multiple Myeloma

Semi-nested PCR Analysis of IgH-gene Rearrangements in the Diagnosis and Follow-Up of B-NHL

Application of Detecting Gene Rearrangement in Diagnosing and Typing of Primary Non-Hodgkin's Lymphoma in Nasal Cavity

Investigation of the Molecular Changes in Patients with Multiple Myeloma by Fluorescence in Situ Hybridization

[The Detection of T-cell Receptor Gene Rearrangement in Myelodysplastic Syndromes].

[Dynamic Monitoring of Minimal Residual Disease in Acute Lymphoid Leukemia].

Study on Molecular Cytogenetic Abnormalities in Multiple Myeloma

[The Diagnostic Significance of Ig Heavy Chain Rearrangement Detected in B Cell Lymphoma Patients' Serum or Plasma Blood Samples].